Immunofoco Reports Promising IMC002 Trial Results
January 14, 2026 | 15:25
The biotech company shared encouraging clinical data at the oncology conference, showing sustained complete response lasting over a year and a two-thirds overall response rate in advanced gastric cancer patients.
Mobile Version